Gossamer Bio (NASDAQ:GOSS) Receives Neutral Rating from Wedbush

Wedbush restated their neutral rating on shares of Gossamer Bio (NASDAQ:GOSS) in a report released on Tuesday, Marketbeat Ratings reports. The brokerage currently has a $1.00 price target on the stock, down from their prior price target of $6.00.

Other equities analysts also recently issued research reports about the stock. Royal Bank Of Canada raised shares of Gossamer Bio to an “outperform” rating in a research note on Tuesday. Wall Street Zen lowered Gossamer Bio from a “hold” rating to a “sell” rating in a research report on Friday, January 23rd. Barclays cut Gossamer Bio from an “overweight” rating to an “underweight” rating in a research note on Tuesday. Leerink Partners lowered Gossamer Bio to a “market perform” rating in a research note on Tuesday. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Gossamer Bio in a report on Thursday, January 22nd. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $6.67.

Gossamer Bio Stock Performance

NASDAQ GOSS opened at $0.42 on Tuesday. Gossamer Bio has a one year low of $0.33 and a one year high of $3.87. The company has a market capitalization of $96.15 million, a price-to-earnings ratio of -0.60 and a beta of 1.93. The company’s 50-day simple moving average is $2.60 and its two-hundred day simple moving average is $2.67.

Institutional Trading of Gossamer Bio

A number of institutional investors have recently bought and sold shares of the stock. State Street Corp grew its position in Gossamer Bio by 139.7% during the 4th quarter. State Street Corp now owns 9,310,969 shares of the company’s stock worth $28,864,000 after purchasing an additional 5,427,302 shares during the last quarter. Corient Private Wealth LLC lifted its stake in shares of Gossamer Bio by 19,123.7% during the fourth quarter. Corient Private Wealth LLC now owns 3,845,885 shares of the company’s stock worth $11,922,000 after buying an additional 3,825,879 shares during the period. Millennium Management LLC grew its holdings in shares of Gossamer Bio by 629.3% during the third quarter. Millennium Management LLC now owns 3,619,329 shares of the company’s stock valued at $9,519,000 after buying an additional 3,123,081 shares during the last quarter. Bank of America Corp DE increased its position in shares of Gossamer Bio by 4,196.2% in the 3rd quarter. Bank of America Corp DE now owns 2,881,904 shares of the company’s stock valued at $7,579,000 after acquiring an additional 2,814,824 shares during the period. Finally, UBS Group AG increased its position in shares of Gossamer Bio by 785.7% in the 3rd quarter. UBS Group AG now owns 2,770,046 shares of the company’s stock valued at $7,285,000 after acquiring an additional 2,457,304 shares during the period. 81.23% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Gossamer Bio

Here are the key news stories impacting Gossamer Bio this week:

• Neutral Sentiment: Company issued a topline results release detailing the PROSERA Phase 3 outcome; the release is the formal source of the miss. Business Wire
• Neutral Sentiment: Analyst action: Wedbush reaffirmed a “neutral” rating but slashed its price target from $6.00 to $1.00, signaling weaker near‑term expectations despite the neutral stance. The Fly
• Neutral Sentiment: Company commentary / transcripts from investor calls and briefings are available and discuss topline details and next steps for regulatory engagement. Seeking Alpha transcript
• Neutral Sentiment: Gossamer says it will still pursue FDA engagement and potential approval pathways despite the late‑stage failure — this leaves a regulatory path, though uncertain. STAT News
• Negative Sentiment: Pivotal trial failure — multiple outlets report seralutinib missed the primary endpoint in PAH, which is the principal driver of the selloff and greater uncertainty about commercial prospects. Reuters
• Negative Sentiment: Shares plunged sharply on the news (reports cite an ~80% intraday drop) and trading was temporarily halted as the market reacted; volume surged well above average — indicating acute volatility and liquidity-driven moves. Investing.com
• Negative Sentiment: Several plaintiff law firms (Block & Leviton, Johnson Fistel and others) are soliciting investors and investigating potential securities‑fraud claims, introducing litigation risk and potential post‑event legal costs. GlobeNewswire (Block & Leviton) GlobeNewswire (Johnson Fistel)
• Negative Sentiment: Wider media coverage (FierceBiotech, MarketWatch, MSN) emphasizes the trial miss and commercial implications, reinforcing negative sentiment and pressuring the stock. FierceBiotech

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.